SMMT - NASDAQ

Good morning, and welcome to the Summit Therapeutics First Quarter 2023 Earnings and Update Call. [Operator Instructions]. At this time, I would like to introduce the call to Dave Gancarz, Senior Vice President of Stakeholder Relations, Business Development and Corporate Strategy. You may proceed.

Good morning, and thank you for joining us. Our press release was issued earlier this morning and is available on the home page of our website. Today's call is being simultaneously webcast, and an archived replay will also be made available later today on our website www.smmttx.com. On the call with me today is Bob Duggan, our Chairman of the Board and Co-Chief Executive Officer; Dr. Maky

Thank you, Dave. It's a pleasure to be on the call with each of you this morning. I'm incredibly proud of the accomplishments of Team Summit over the past few months since we closed our transaction with the world-class partners at Akeso. Our relationship discussions with Akeso began in July of 2022 through our business development channels. By October, we had achieved a vision and a concept of what a partnership with Akeso, including their bispecific drug, ivonescimab, could potentially generate under Team Summit's stewardship. Throughout November, we gained additional data and evaluated it properly on not only the company, but the product itself. As we gained additional direct experience with Akeso's team leadership and specifically with Dr. Michelle Xia, Akeso's CEO, founder and Chairwoman, we were able to then lead on to a December 5 truly historic day and transaction for all of us. We signed a $5 billion and $500 million upfront transaction with Akeso. By entering into this transaction, we committed to our stakeholders consistent with our mission statement to take full responsibility for the development of ivonescimab along with that we intend -- stated that we intended to make a significant positive difference for human health care by improving the quality of patient lives and potentially the duration of patient lives for most patients who may benefit from this medicine. I'm proud to say that we are making significant strides towards fulfilling that commitment. And Maky will provide us with additional details shortly regarding our progress on that. Finally, from a corporate governance perspective, we are proud to have added Dr. Michelle Xia to our Board of Directors this quarter in conjunction with closing Akeso transaction. As you may know, but it's worth repeating, if you do, Dr. Xia, who founded Akeso in 2012, is their Chairwoman and CEO. She has exceptional experience in leadership across scientific discovery, R&D, building and scaling manufacturing and overall leadership through her experience at companies in the U.S., including Celera Genomics, Bayer and Crown Bioscience. At Crown, she played a decisive role in constructing the company's platform as she served in a leadership role in a joint venture with Pfizer. Dr. Xia has about 20 years of experience in the pharmaceutical industry and academic research in the U.S. and U.K., in addition to her deep experience in leading the Chinese company, Akeso. And with that, I would like to hand it over to Maky to provide additional context as to our accomplishments and next steps. Maky?

Thank you, Bob, and good morning, everyone. I'm incredibly enthusiastic about our collaboration with Akeso. Akeso has a rich and diversified antibody drug pipeline with over 30 internally discovered drug candidates in various stages of development, including 6 bispecific antibodies. Akeso has taken part in over 80 clinical trials for 17 drug candidates, including 14 pivotal trials. Akeso has 2 drugs approved for oncology indication in China, a PD-1 inhibitor and a novel PD-1/CTLA-4 bispecific antibody called cadonilimab. Cadonilimab is the first PD-1-based bispecific antibody approved in any major market, demonstrating Akeso expertise and innovation in this space. Akeso has over 2,400 employees who perform end-to-end functions of a fully integrated biopharma company from drug discovery through to manufacturing and commercialization, and is publicly listed in Hong Kong with a valuation approaching USD 5 billion. Specific to our product candidate, ivonescimab is an innovative, potentially first-in-class bispecific antibody that is intended to change the standard of care across several oncological indications. Ivonescimab combines the effect of immunotherapy via a blockade of PD-1 with anti-angiogenesis effects associated with VEGF into a single molecule. Anti-PD-1 therapy assists the immune system in killing tumor cells. Anti-VEGF therapy helps deplete the tumor of new blood vessels and allows the immune system to fight the tumor. Ivonescimab's tetravalent structures enables higher avidity, which is the accumulated strength of multiple binding interactions with over 10x the binding affinity to PD-1 in the presence of VEGF in vitro in tumor cells. This tetravalent structure, the design of the molecule and bringing these 2 targets into a single bispecific antibody have the potential to steer ivonescimab to the tumor tissue versus healthy tissue, which could lead to reduced adverse events associated with this target when administered individually. It also has the potential to focus the antitumor activity of both targets as compared to separate anti-PD-1 and anti-VEGF compounds dosed together. As Bob said, I'm extremely proud of the work and accomplishment of Team Summit over the past several months since we have reached an agreement with Akeso. We began our work formulating our ideas on the development of ivonescimab during our due diligence process in the second half of last year. Once we signed the deal in December and the agreement went effective in January, we have pushed very hard on bringing to life the vision that we set out at the start of this collaboration. We immediately engaged with health authorities in our licensed territories, including the U.S. FDA. We held multiple meetings with the FDA to discuss multiple Phase III clinical trials as part of our late-stage development plan in a non-small cell lung cancer for ivonescimab. We appreciated and incorporated feedback from the FDA when finalizing the design of our 2 clinical studies, which we announced last week. They are ivonescimab combined with chemotherapy in patients with EGFR-mutated, locally advanced or metastatic nonsquamous non-small cell lung cancer who have progressed after treatment with a third-generation EGFR TKI, such as osimertinib, which we refer to as the HARMONi trial. The second trial, ivonescimab, combined with chemotherapy in first-line metastatic squamous non-small cell lung cancer patients, which we call the HARMONi-3 trial. This study will combine patients enrolled in China, along with patients enrolled in the United States, Canada and Europe as a multiregional randomized, double-blind study enrolling over 400 patients across these regions. In supporting these clinical trials, we are executing up in a number of different areas including the work to begin clinical trials with different trial sites and vendors such as preparing clinical study sites to enroll patients and all of the foundational work needed to launch a clinical study including contracts, institutional review board approvals and quality reviews. Critical to all of this is the engagement with key opinion leaders and aligning feedback from this highly engaged physicians with the data generated from Akeso, having treated over 750 patients with ivonescimab to date in China and Australia in order to successfully generate the momentum needed to enroll each study as effectively and efficiently as possible. In addition to preparing clinical drug supply for trials in our territory, we have been actively preparing to expand our supply chain channel long term with respect to having the opportunity to obtain clinical and commercial supply for multiple sources. Because of the hard work and effort across our entire team and the support from our partner at Akeso, we have initiated our first clinical study in our territory HARMONi. We were thrilled to announce earlier this week that we have enrolled our first patient in the HARMONi study, a feat accomplished in about 3.5 months after our deal closed with Akeso. We are following up for the achievement with our intent to initiate HARMONi-3 and enroll patients in this study in the second half of this year. As we have stated since the announcement of the deal in conjunction with our actions and following through of our commitments to start in a non-small cell lung cancer. These 2 clinical trials are only the first step with respect to our plans for ivonescimab. We have confidence in ivonescimab to continue to expand both with an additional indication in non-small cell lung cancer and in other solid tumors during its development life cycle. Our deal was constructed with this mindset as is evident from the number of indications for which regulatory milestones are scheduled to be paid as well as the size of the potential milestone. We believe strongly in the potential of ivonescimab. As a reminder, our collaboration and license agreement provide us with the rights to ivonescimab in the United States, Canada, Europe and Japan. In exchange for these rights, we paid $500 million upfront to Akeso. And Akeso is eligible to receive regulatory milestone of to $1.05 billion and commercialization milestone of up to $3.45 billion. Akeso will receive low double-digit royalty on all net sales of SMT112. We continue to build up and establish actions and data created by Akeso and the deal we have consummated. Our team has made multiple visits to Akeso in the past few months and spent meaningful time in person with Akeso leadership over the past 8 months in order to continue to build the success of Akeso earlier-stage clinical trials and propel our collaboration to the next level as we continue to work together to achieve the best results and realize the potential of ivonescimab. Our aligned missions each of which focus on patients' needs and improve patient lives allow for allowing intention within our partnership and the future of ivonescimab. My confidence cannot be higher in Team Summit's ability to make a meaningful impact on the lives of patients who can benefit from this innovative therapy, both in non-small cell lung cancer and other solid tumors. This is just the beginning. Now I will let Ankur give some more details on our financial position and outlook.

Thank you, Maky. These are very exciting times at Summit. With ivonescimab, we have a great opportunity in front of us to improve patients' lives, and I'm very pleased with the progress that team has made in this short duration of time. I will now give you an update on the financial developments during the quarter and our financial position as of the end of the quarter. During the quarter, we completed significant purchasing and financing transactions. First, we completed the in-licensing deal with Akeso and paid them $500 million as upfront consideration. This was paid via approximately $475 million in cash and 10 million shares of Summit's common stock. Second, we successfully completed our rights offering of $500 million. This offering was oversubscribed with broad-based participation. Third, we repaid $420 million of the loans this quarter, and are left with $100 million of loan on our balance sheet, which becomes due in September 2024. Fourth, we announced that we are ceasing investment in our anti-infectives business, focusing our resources on development of ivonescimab. And most importantly, we did all the foundational work that Maky described towards initiation of 2 Phase III clinical trials. It's been a busy quarter. Now about the P&L. Net loss for the quarter was $542.4 million, included therein is $520.9 million of IP R&D expenses, which reflects the upfront payment made to Akeso for in-licensing of ivonescimab, comprising of $474.9 million in cash payment and 10 million shares issued to Akeso with accounting valuation of $45 million reflecting market price on the date the shares were issued. Excluding this onetime payment, pro forma net loss was about $22 million, of which our operating expenses were $16.8 million. Talking about our cash position. We exited the quarter with $242 million in cash and investments. We believe this is sufficient to fund our operating cost and working capital needs for currently planned clinical trials for SMT112 going into the second half of 2024. This includes appropriately building an experienced oncology team capable of executing multiple large clinical trials and the related development work. We have a loan of $100 million on our balance sheet that becomes due on September 2024 and have ability to prepay in certain scenarios if we complete a capital raise transaction prior to September 2024. Also to note, all our cash equivalents and investments are held in highly liquid and highly rated money market funds or U.S. treasuries and the cash is held in large U.S. and European banks. To sum up, in last few months, we've taken significant actions since closing the deal for the in-licensing of ivonescimab, a significant amount of groundwork leading to announcement of 2 late-stage multi-region trials and treatment of first patient in our first trial. We also laid a solid financial foundation for investment in our planned clinical studies and the development of ivonescimab. And with that, I will hand it back over to Dave.

Thank you, Bob, Maky and Ankur. We can now transition if there are any questions that we could answer. If we could please open the line for questions.

[Operator Instructions].

Thank you, Kayla. And we have received a couple of questions first. So I'll start with those questions, and then we can transition to those on the phone. The first question comes in relates to the Phase III clinical trials that we plan to conduct, and whether or not we will be able to submit any data that has been compiled and generated by Akeso as opposed to just that data that has been generated by Summit. So I'll take the first part of that question, then I'll hand it over to Urte, who's our Head of Regulatory, Safety and Quality. So our HARMONi trial will enroll patients in the United States, Canada, Europe and China. Those patients coming from China will be enrolled by our partners at Akeso. So our intent is to include data that is generated by our partners at Akeso specifically for this trial.

Yes. This is Urte Gayko. Yes, we will definitely be able to utilize information coming from both Akeso side as well as the data that we are generating. The most important part for the is that we have appropriately designed -- trials with the important health authority for the U.S., obviously, the FDA in the context of multiregional studies. We have actually discussed exactly how to do this appropriately for our Phase III studies and have given an agreement on that, specifically with FDA and are executing in this context.

Thank you, Urte. And one additional question that we've received. With respect to certain designations from the FDA, such as breakthrough therapy designation, Fast Track designation what can the company do in order to seek to achieve those designations if they're appropriate?

So I think both of these designations are of interest and likely relevant for ivonescimab. So Fast Track first. So I think we are a strong candidate for Fast Track, and are likely to pursue this designation. We have also started as it relates to breakthrough designation consultation with FDA specifically what kind of data set would be most appropriate to pursue that designation. And we will continue this consultation with FDA. So both of them are very relevant for us, and we are likely candidates.

Kayla, any additional questions?

[Operator Instructions]. And there are no audio questions at this time. Dave, I'll turn the call back to you.

Perfect. Thank you very much. I would like to thank you for your participation in this. And with that, they will be an archived version of this webcast that will be available on our website, www.smmttx.com. Thank you, and we wish you a great day.